Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment
MetadataShow full item record
Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type being venous thromboembolism (VTE). Several risk factors for developing VTE also coexist with cancer patients, such as chemotherapy and immobilisation, contributing to the increased risk cancer patients have of developing VTE compared with non-cancer patients. Cancer cells are capable of activating the coagulation cascade and other prothrombotic properties of host cells, and many anticancer treatments themselves are being described as additional mechanisms for promoting VTE. This review will give an overview of the main thrombotic complications in cancer patients and outline the risk factors for cancer patients developing cancer-associated thrombosis, focusing on VTE as it is the most common complication observed in cancer patients. The multiple mechanisms involved in cancer-associated thrombosis, including the role of anticancer drugs, and a brief outline of the current treatment for cancer-associated thrombosis will also be discussed.
Showing items related by title, author, creator and subject.
Pancreatic cancer-induced neutrophil extracellular traps: A potential contributor to cancer-associated thrombosisRazak, N.; Elaskalani, O.; Metharom, Pat (2017)Pancreatic cancer (PaCa) is a highly metastatic cancer, and patients are at high risk of developing venous thromboembolism (VTE). Neutrophil extracellular traps (NETs) have been associated with cancer metastasis and ...
Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patientsSinha, D.; Chong, L.; George, J.; Schlüter, H.; Mönchgesang, S.; Mills, S.; Li, J.; Parish, C.; Bowtell, D.; Kaur, Pritinder (2016)Purpose: The aim of this study was to investigate the role of pericytes in regulating malignant ovarian cancer progression. Experimental Design: The pericyte mRNA signature was used to interrogate ovarian cancer patient ...
Adamska, A.; Elaskalani, O.; Emmanouilidi, A.; Kim, M.; Abdol Razak, N.; Metharom, P.; Falasca, Marco (2017)Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation ...